Your AI-Trained Oncology Knowledge Connection!

Phillippe Aftimos

Articles by Phillippe Aftimos

26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

ByVirginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH,Phillippe Aftimos,Javier Cortes,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,François-Clément Bidard

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma

Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer

Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer

Managing BCMA/GPRC5D-Associated CRS and ICANS in the Real-World Setting

Adjuvant Endocrine/Radiation Therapy May Limit Breast Cancer Recurrence

© 2025 MJH Life Sciences^®

All rights reserved.